Navigation Links
Champions' CFO Resigns

BALTIMORE, Jan. 14, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced today the resignation of Mark Schonau, Champions' Chief Financial Officer. Mr. Schonau indicated that he has no disagreements with management and has resigned to pursue other opportunities. Champions is seeking chief financial officer candidates and intends to complete the search in the near future.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced translational platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Technology Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Champions Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

Contact: Joel Ackerman, CEO, 410 369 0365

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology Awarded $1.46 million in Grants
2. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
3. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
4. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
9. John A. MacPhee Resigns From Strativa Pharmaceuticals
10. Paul D. Duke Resigns From Mesas Board of Directors
Post Your Comments:
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... CHICAGO , Oct. 11, 2017  Hill-Rom Holdings, ... its Aspen Surgical facility in Las Piedras, ... surgical scalpels and blades. ... confirmed that the facility sustained minor structural damage, temporary ... Hurricane Maria. Repairs have been completed, manufacturing operations have ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):